Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-3-13
pubmed:abstractText
The effect of rapamycin (RAPA) on both host-versus-graft (HVG) and graft-versus-host (GVH) immune responses was examined in small bowel transplant models using strongly histoincompatible donor-recipient combinations. Normal Wistar Furth (WFu; RT-1u) recipients rejected Buffalo (BUF; RT-1b) small bowel allografts within a mean survival time (MST) of 10.5 +/- 0.5 days. Administration of RAPA (0.8 mg/kg) by continuous intravenous infusion for 14 days via an osmotic pump prolonged graft survival to 25.0 +/- 4.6 days (P = 0.01). In a second strain combination, the 12.5 +/- 2.2 day survival of Brown Norway (BN; RT-1n) small bowel allografts in Lewis (RT-1l) recipients was prolonged to 21.6 +/- 2.0 and 28.5 +/- 2.8 days by 14 days of i.v. RAPA at doses of 0.8 and 1.6 mg/kg, respectively. In this model RAPA is five times more effective than cyclosporine, which at 4.0 mg/kg prolongs BN small bowel allografts in Lewis recipients to 21.6 +/- 6.3. To isolate HVG and GVH immune responses, (BN x Lewis)F1 hybrid rats served as the graft donor or host, respectively. In the HVG model, (BN x Lewis)F1 small bowel allografts, which were rejected by normal Lewis recipients at 12.2 +/- 3.6 days, were prolonged to 40.8 +/- 5.8 days (P = 0.001) by RAPA (0.8 mg/kg x 14 days). In the GVH model, the ability of Lewis small bowel allografts to produce severe GVH disease in untreated (BN x Lewis)F1 recipients at 12.3 +/- 2.8 days was delayed to 21.3 +/- 5.2 days by 0.8 mg/kg RAPA (P = 0.025). Thus, RAPA protects small bowel allografts more effectively against HVG than GVH immune responses.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0041-1337
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
258-64
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:1738917-Animals, pubmed-meshheading:1738917-Body Weight, pubmed-meshheading:1738917-Cyclosporine, pubmed-meshheading:1738917-Dose-Response Relationship, Drug, pubmed-meshheading:1738917-Graft Survival, pubmed-meshheading:1738917-Graft vs Host Reaction, pubmed-meshheading:1738917-Host vs Graft Reaction, pubmed-meshheading:1738917-Immunosuppressive Agents, pubmed-meshheading:1738917-Intestinal Absorption, pubmed-meshheading:1738917-Intestine, Small, pubmed-meshheading:1738917-Male, pubmed-meshheading:1738917-Maltose, pubmed-meshheading:1738917-Polyenes, pubmed-meshheading:1738917-Rats, pubmed-meshheading:1738917-Rats, Inbred BN, pubmed-meshheading:1738917-Rats, Inbred BUF, pubmed-meshheading:1738917-Rats, Inbred Lew, pubmed-meshheading:1738917-Rats, Inbred WF, pubmed-meshheading:1738917-Sirolimus, pubmed-meshheading:1738917-Transplantation, Homologous
pubmed:year
1992
pubmed:articleTitle
Inhibition of host-versus-graft and graft-versus-host responses after small bowel transplantation in rats by rapamycin.
pubmed:affiliation
Department of Surgery, University of Texas Medical School, Houston 77030.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't